Cost-effectiveness and Durability of the Shingles Vaccine

To view some of the files in this section, you will require a version of Adobe Acrobat. This is free to download and is available on the Adobe Acrobat website.

To view the PowerPoint presentations you will require Microsoft PowerPoint. You can download the latest PowerPoint viewer free from the Microsoft website.

You are welcome to download, view and use many of the slides contained in these presentations, however the original presenter and IHMF^Ž must be suitably acknowledged for any use, for example in oral presentations or written material. Please also be aware that some slides contain graphs, illustrations or other content that may not be the copyright of the presenter or the IHMF^Ž and permission ot use such material will need to be obtained from the copyright owner prior to use. Some of the slide presentations from the 13th IHMF^Ž Annual Meeting are subject to 'restricted use' and the presentations to which this applies are labelled with the notice 'Restricted Use - please contact the presenter prior to any use of the content of this presentation'. These 'restricted use' presentations may only be viewed online or downloaded to view, and the original presenter must be contacted prior to any use.

If you are in any doubt about your use of this material, please contact the IHMF Secretariat.

Cost-effectiveness and Durability of the Shingles Vaccine

Marc Brisson, PhD
Canadian Research Chair in Mathematical Modeling and Health Economics of Infectious Disease
Associate Professor, Université Laval

Background: The Shingles Prevention Study (SPS) showed that a varicella-zoster virus vaccine is effective against herpes zoster (HZ) and postherpetic neuralgia (PHN). The aim of this study was to examine the duration of protection and the cost-effectiveness of the HZ vaccine.

Methods: We developed a cohort model to estimate the duration of protection of the HZ vaccine and the cost-effectiveness of HZ vaccination in Canada. Duration of vaccine protection was estimated by fitting the model to the age-specific SPS data. The economic evaluation was conducted from the health care payer perspective. Different ages at vaccination were examined and sensitivity analysis was performed.

Results: The best fit annual waning rate of protection was 0.000 per person-year (95%CI: 0.000, 0.083), which suggests that the average duration of vaccine efficacy is greater than 12 years (1/0.083 person-years). Furthermore, using $40,000 per Quality-Adjusted Life-Year (QALY) gained as strong evidence for cost-effectiveness, HZ vaccination was found to be cost-effective over a wide range of parameter assumptions and scenarios for adults aged between 60 and 75 years.

Conclusion: Results suggest that vaccinating adults between the ages of 60 and 75 years will likely be cost-effective. This result, however, depends highly on the duration of vaccine protection.

View

Download

The IHMFŽ is a registered trademark of PAREXEL MMS

Last Updated : 11/12/2007 11:57:55